دورية أكاديمية
أعرض في EDS

Heterologous prime-boost with the mRNA-1273 vaccine among CoronaVac-vaccinated healthcare workers in Indonesia.

التفاصيل البيبلوغرافية
العنوان: Heterologous prime-boost with the mRNA-1273 vaccine among CoronaVac-vaccinated healthcare workers in Indonesia.
المؤلفون: Santi T; Siloam Hospitals Lippo Cikarang, Bekasi, Indonesia., Sungono V; Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia., Kamarga L; Siloam Hospitals Lippo Cikarang, Bekasi, Indonesia., Samakto B; Siloam Hospitals Lippo Cikarang, Bekasi, Indonesia., Hidayat F; Siloam Hospitals Lippo Cikarang, Bekasi, Indonesia., Hidayat FK; Siloam Hospitals Lippo Cikarang, Bekasi, Indonesia., Satolom M; Siloam Hospitals Lippo Cikarang, Bekasi, Indonesia., Permana A; Siloam Hospitals Lippo Cikarang, Bekasi, Indonesia., Yusuf I; Faculty of Medicine, Hasanuddin University, Makassar, Indonesia.; Mochtar Riady Institute for Nanotechnology, Tangerang, Indonesia., Suriapranata IM; Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia.; Mochtar Riady Institute for Nanotechnology, Tangerang, Indonesia., Jo J; Mochtar Riady Institute for Nanotechnology, Tangerang, Indonesia.; Department of Biology, Faculty of Science and Technology, Universitas Pelita Harapan, Tangerang, Indonesia.
المصدر: Clinical and experimental vaccine research [Clin Exp Vaccine Res] 2022 May; Vol. 11 (2), pp. 209-216. Date of Electronic Publication: 2022 May 31.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Korean Vaccine Society Country of Publication: Korea (South) NLM ID: 101592344 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2287-3651 (Print) Linking ISSN: 22873651 NLM ISO Abbreviation: Clin Exp Vaccine Res Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Seoul : Korean Vaccine Society
مستخلص: Purpose: This study was performed to investigate humoral immune response and adverse events upon the heterologous prime-boost with a single dose of the mRNA-1273 vaccine among fully CoronaVac-vaccinated, infection-naïve healthcare workers in Indonesia.
Materials and Methods: One hundred twenty-five eligible healthcare workers were recruited from one hospital for this prospective cohort study. Blood collection was conducted twice, i.e., on 7 days before and 28 days after the booster vaccination. The titer of anti-SARS-CoV-2 receptor-binding domain (RBD) antibodies was quantified accordingly. The post-vaccination adverse event was recorded for both CoronaVac and mRNA-1273 vaccinations. Any breakthrough infection was monitored during the follow-up period. Wilcoxon matched-pairs signed rank test was used to test differences between groups.
Results: A significant increase was observed in the titer of anti-SARS-CoV-2 RBD antibodies upon receiving the mRNA-1273 booster (geometric mean titers of 65.57 and 47,445 U/mL in pre- and post-booster, respectively), supporting the argument to use heterologous prime-boost vaccination to improve the protection against COVID-19 in a high-risk population. The mRNA-1273 vaccine, however, caused a higher frequency of adverse events than the CoronaVac vaccine. Nonetheless, the adverse events were considered minor medical events and temporary as all subjects were not hospitalized and fully recovered. Of note, no breakthrough infection was observed during the follow-up to 12 weeks post-booster.
Conclusion: The heterologous prime-boost vaccination of healthcare workers with a single dose of the mRNA-1273 vaccine generated a significant elevation in humoral immune response towards RBD of SARS-CoV-2 and was associated with a higher frequency, but minor and transient, adverse events.
Competing Interests: No potential conflict of interest relevant to this article was reported.
(© Korean Vaccine Society.)
References: Front Immunol. 2022 Jan 19;12:798117. (PMID: 35126362)
Front Immunol. 2021 Apr 12;12:669339. (PMID: 33912196)
Expert Rev Vaccines. 2021 Oct;20(10):1211-1220. (PMID: 34415818)
N Engl J Med. 2020 Nov 12;383(20):1920-1931. (PMID: 32663912)
N Engl J Med. 2021 Sep 2;385(10):875-884. (PMID: 34233097)
Nat Biotechnol. 2020 Sep;38(9):1073-1078. (PMID: 32704169)
N Engl J Med. 2021 Feb 4;384(5):403-416. (PMID: 33378609)
Clin Exp Vaccine Res. 2022 Jan;11(1):116-120. (PMID: 35223672)
Nature. 2021 Nov;599(7883):114-119. (PMID: 34488225)
Nat Med. 2021 Dec;27(12):2136-2143. (PMID: 34728831)
Br J Anaesth. 2008 Jul;101(1):17-24. (PMID: 18487245)
BMJ. 2021 Jul 16;374:n1815. (PMID: 34272255)
Nature. 2022 Jan;601(7891):110-117. (PMID: 34758478)
Lancet Infect Dis. 2022 Jan;22(1):56-63. (PMID: 34509185)
Int J Infect Dis. 2021 Dec;113:15-17. (PMID: 34614445)
Nature. 2021 Oct;598(7881):398-399. (PMID: 34650240)
Clin Exp Vaccine Res. 2021 Sep;10(3):282-289. (PMID: 34703812)
Clin Microbiol Infect. 2022 Apr;28(4):612.e1-612.e7. (PMID: 34826623)
Curr Opin Immunol. 2009 Jun;21(3):346-51. (PMID: 19500964)
Nature. 2021 Aug;596(7873):472-473. (PMID: 34417582)
Vaccine. 2022 May 20;40(23):3203-3209. (PMID: 35465981)
Lancet Infect Dis. 2021 Feb;21(2):181-192. (PMID: 33217362)
Emerg Microbes Infect. 2021 Dec;10(1):1598-1608. (PMID: 34278956)
NPJ Vaccines. 2019 Sep 24;4:39. (PMID: 31583123)
Acta Med Indones. 2021 Jul;53(3):326-330. (PMID: 34611073)
Nature. 2020 Dec;588(7839):682-687. (PMID: 33045718)
فهرسة مساهمة: Keywords: 2019-nCoV vaccine mRNA-1273; Anti-SARS-CoV-2 RBD; CoronaVac; Coronavirus disease 2019; Heterologous prime-boost
تواريخ الأحداث: Date Created: 20220708 Latest Revision: 20220716
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9200645
DOI: 10.7774/cevr.2022.11.2.209
PMID: 35799870
قاعدة البيانات: MEDLINE
الوصف
تدمد:2287-3651
DOI:10.7774/cevr.2022.11.2.209